Reference:ICH ICH E8 Guideline R1 (2021) 5.: Difference between revisions
From GxPlex
gxplex>GxPlexBot Import from GxPlex Excel |
Gxplex admin (talk | contribs) m 1 revision imported |
||
| (6 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
{{ | {{ReferenceData | ||
| | |has_document=Document:ICH ICH E8 Guideline R1 (2021) | ||
| | |module=2 | ||
| | |unit=2.1.3 | ||
| | |scope=HM | ||
| | |doc_part=5. | ||
| | |language=EN | ||
| | |entry_by=Florian Adragna | ||
|contributors= | |||
|tags=TAG-00033-Pro-oto ++ TAG-00302-Ada-die ++ TAG-00055-Stu-ngs ++ TAG-00011-Inv-tud | |||
|tags_display=[[Glossary:TAG-00033-Pro-oto|Protocol]], [[Glossary:TAG-00302-Ada-die|Adaptive design]], [[Glossary:TAG-00055-Stu-ngs|Study design]], [[Glossary:TAG-00011-Inv-tud|Investigational drug (IMP)]] | |||
|comment=Design elements for master protocol and platform trial studies | |||
|content=5. DESIGN ELEMENTS AND DATA SOURCES FOR CLINICAL STUDIES | |||
|- | |||
|- | |||
|- | |||
|- | |||
| | |||
| | |||
| | |||
= | |||
5. DESIGN ELEMENTS AND DATA SOURCES FOR CLINICAL STUDIES | |||
[…] | […] | ||
Master protocol studies allow for the investigation of multiple drugs or multiple conditions under a shared framework. | Master protocol studies allow for the investigation of multiple drugs or multiple conditions under a shared framework. | ||
Platform studies allow for multiple drugs to be investigated in a continuous manner, with different drugs entering the study at different times and leaving the study based on pre-specified decision rules. | Platform studies allow for multiple drugs to be investigated in a continuous manner, with different drugs entering the study at different times and leaving the study based on pre-specified decision rules. | ||
}} | |||
Latest revision as of 13:49, 16 July 2026
| Document information | |
|---|---|
| Reference | ICH ICH E8 Guideline R1 (2021) |
| Validity area | ICH |
| Scope(s) | HM |
| Document name | ICH E8 Guideline |
| Version / Revision | R1 (2021) |
| Status | Current |
| Document type | International guideline |
| Language(s) | EN |
| Description | ICH guideline E8 (R1) on general considerations for clinical studies |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 2 — Unit 2.1.3 |
| Scope | HM |
| Document part | 5. |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Protocol, Adaptive design, Study design, Investigational drug (IMP) |
Content
5. DESIGN ELEMENTS AND DATA SOURCES FOR CLINICAL STUDIES […] Master protocol studies allow for the investigation of multiple drugs or multiple conditions under a shared framework. Platform studies allow for multiple drugs to be investigated in a continuous manner, with different drugs entering the study at different times and leaving the study based on pre-specified decision rules.
